Natalia Quintella Sangiorgi Olivetti

Dr. Natalia Quintella Sangiorgi Olivetti

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 July 2023 in EP Europace
Verified
Journal Article
Open access
PDF file
NPNemer L Pichara
Nemer L Pichara
LSLuciana Sacilotto
Luciana Sacilotto
MSMaurício Scanavacca
Maurício Scanavacca
ACAcácio Fernandes Cardoso
Acácio Fernandes Cardoso
BSBeatriz Moreira Ayub Ferreira Soares
Beatriz Moreira Ayub Ferreira Soares
WCWilliam A Chalela
William A Chalela
High precordial leads (HPL) on the resting electrocardiogram (ECG) are widely used to improve diagnostic detection of type 1 Brugada ECG pattern (Br1ECGp). A parasympathetic activation marks the initial recovery phase of treadmill stress testing (TET), and this can be useful for detecting the typical ECG pattern. Our study aimed to evaluate the role of a new HPL-treadmill exercise testing (TET) protocol in detecting Br1ECGp fluctuation compared to resting HPL-ECG. 74 out of 163 patients of a Brugada syndrome (BrS) Brazilian cohort (GenBra Registry) underwent exercise testing with HPL-TET protocol. Precordial leads were displayed in strategic positions in the right and left parasternal spaces. The step-by-step analysis included ECG classification (as presence or absence of Br1ECGp) in standard vs. HPL leads placement in the following sequences: resting phase, maximal exercise, and the passive recovery phase (including ‘quick lay down’). For heart rate recovery (HRR) measurements and comparisons, a Student’s t-test was applied. McNemar tests compared the detection of Br1ECGp. The significance level was defined as P < 0.05. Fifty-seven patients (57/74; 77%) were male, the mean age was 49.0 ± 14, 78.4% had spontaneous BrS, and the mean Shanghai score was 4.5. The HPL-TET protocol increased Br1ECGp detection by 32.4% against resting HPL-ECG (52.7% vs. 20.3%, P = 0.001) alone. Stress testing using HPL with the passive recovery phase in the supine position offers an opportunity to unmask the type 1 Br1ECGp, which could increase the diagnostic yield in this population.

1 February 2023 in Circulation: Arrhythmia and Electrophysiology
Verified
Journal Article
Closed access
NONatalia Quintella Sangiorgi Olivetti
Natalia Quintella Sangiorgi Olivetti
LSLuciana Sacilotto
Luciana Sacilotto
FWFanny Wulkan
Fanny Wulkan
GPGabrielle D'Arezzo Pessente
Gabrielle D'Arezzo Pessente
MCMARIANA LOMBARDI PERES DE CARVALHO
MARIANA LOMBARDI PERES DE CARVALHO
FDFrancisco Carlos da Costa Darrieux
Francisco Carlos da Costa Darrieux
Background:Arrhythmogenic right ventricular cardiomyopathy (ARVC), a rare inherited disease, causes ventricular tachycardia, sudden cardiac death, and heart failure (HF). We investigated ARVC clinical features, genetic findings, natural history, and the occurrence of life-threatening arrhythmic events (LTAEs), HF death, or heart transplantation (HF-death/HTx) to identify risk factors. Methods:The clinical course of 111 consecutive patients with definite ARVC, predictors of LTAE, HF-death/HTx, and combined events were analyzed in the entire cohort and in a subgroup of 40 patients without sustained ventricular arrhythmia before diagnosis. Results:The 5-year cumulative probability of LTAE was 30% and HF-death/HTx was 10%. Predictors of HF-death/HTx were reduced right ventricle ejection fraction (HR: 0.93; P=0.010), HF symptoms (HR: 4.37; P=0.010), epsilon wave (HR: 4.99; P=0.015), and number of leads with low QRS voltage (HR: 1.28; P=0.001). Each additional lead with low QRS voltage increased the risk of HF-death/HTx by 28%. Predictors of LTAE were prior syncope (HR: 1.81; P=0.040), number of leads with T wave inversion (HR: 1.17; P=0.039), low QRS voltage (HR: 1.12; P=0.021), younger age (HR: 0.97; P=0.006), and prior ventricular arrhythmia/ventricular fibrillation (HR: 2.45; P=0.012). Each additional lead with low QRS voltage increased the risk of LTAE by 17%. In patients without ventricular arrhythmia before clinical diagnosis of ARVC, the number of leads with low QRS voltage (HR: 1.68; P=0.023) was independently associated with HF-death/HTx. Conclusions:Our study demonstrated the characteristics of a specific cohort with a high prevalence of arrhythmic burden at presentation, male predominance, younger age and HF severe outcomes. Our main results suggest that the presence and extension of low QRS voltage can be a risk predictor for HF-death/HTx in ARVC patients, regardless of the arrhythmic risk. This study can contribute to the global ARVC risk stratification, adding new insights to the international current scientific knowledge.

1 October 2023 in Arquivos Brasileiros de Cardiologia
Verified
Journal Article
Open access
PDF file
SFSilas Ramos Furquim
Silas Ramos Furquim
BLBianca Linnenkamp
Bianca Linnenkamp
NONatalia Quintella Sangiorgi Olivetti
Natalia Quintella Sangiorgi Olivetti
FGFernando Rabioglio Giugni
Fernando Rabioglio Giugni
LLLayara Fernanda Vicente Pereira Lipari
Layara Fernanda Vicente Pereira Lipari
JKJosé Eduardo Krieger
José Eduardo Krieger
Resumo Os testes genéticos para cardiomiopatia dilatada (CMD) apresentam uma positividade de até 40%, mas há uma grande heterogeneidade genética e outros desafios decorrentes de expressividade variável e penetrância incompleta. O heredograma é fundamental para diferenciar os casos de CMD esporádica e familiar, por meio da avaliação do histórico familiar. A CMD familiar apresenta um rendimento maior nos testes genéticos, mas a CMD esporádica não exclui a possibilidade de causa genética. Alguns genes têm fenótipos específicos, sendo o gene da [...] Resumo Os testes genéticos para cardiomiopatia dilatada (CMD) apresentam uma positividade de até 40%, mas há uma grande heterogeneidade genética e outros desafios decorrentes de expressividade variável e penetrância incompleta. O heredograma é fundamental para diferenciar os casos de CMD esporádica e familiar, por meio da avaliação do histórico familiar. A CMD familiar apresenta um rendimento maior nos testes genéticos, mas a CMD esporádica não exclui a possibilidade de causa genética. Alguns genes têm fenótipos específicos, sendo o gene da

9 January 2024 in Diagnostics
Verified
Journal Article
Open access
PDF file
NONatalia Quintella Sangiorgi Olivetti
Natalia Quintella Sangiorgi Olivetti
LSLuciana Sacilotto
Luciana Sacilotto
DMDanilo Bora Moleta
Danilo Bora Moleta
LFLucas Arraes de França
Lucas Arraes de França
LCLorena Squassante Capeline
Lorena Squassante Capeline
FDFrancisco Carlos da Costa Darrieux
Francisco Carlos da Costa Darrieux
Introduction: The echocardiographic diagnosis criteria for arrhythmogenic right ventricular cardiomyopathy (ARVC) are highly specific but sensitivity is low, especially in the early stages of the disease. The role of echocardiographic strain in ARVC has not been fully elucidated, although prior studies suggest that it can improve the detection of subtle functional abnormalities. The purposes of the study were to determine whether these advanced measures of right ventricular (RV) dysfunction on echocardiogram, including RV strain, increase diagnostic value for ARVC disease detection and to evaluate the association of echocardiographic parameters with arrhythmic outcomes. Methods: The study included 28 patients from the Heart Institute of São Paulo ARVC cohort with a definite diagnosis of ARVC established according to the 2010 Task Force Criteria. All patients were submitted to ECHO’s advanced techniques including RV strain, and the parameters were compared to prior conventional visual ECHO and CMR. Results: In total, 28 patients were enrolled in order to perform ECHO’s advanced techniques. A total of 2/28 (7%) patients died due to a cardiovascular cause, 2/28 (7%) underwent heart transplantation, and 14/28 (50%) patients developed sustained ventricular arrhythmic events. Among ECHO’s parameters, RV dilatation, measured by RVDd (p = 0.018) and RVOT PSAX (p = 0.044), was significantly associated with arrhythmic outcomes. RV free wall longitudinal strain < 14.35% in absolute value was associated with arrhythmic outcomes (p = 0.033). Conclusion: Our data suggest that ECHO’s advanced techniques improve ARVC detection and that abnormal RV strain can be associated with arrhythmic risk stratification. Further studies are necessary to better demonstrate these findings and contribute to risk stratification in ARVC, in addition to other well-known risk markers.

1 May 2025 in ABC Heart Failure & Cardiomyopathy
Verified
Journal Article
Open access
PDF file
NONatalia Quintella Sangiorgi Olivetti
Natalia Quintella Sangiorgi Olivetti
MPMárya Pagotti
Márya Pagotti
BSBruno Moreira Santos
Bruno Moreira Santos
MMMarjorie Mizuta
Marjorie Mizuta
BLBianca Linnenkamp
Bianca Linnenkamp
JKJose Krieger
Jose Krieger
Filamin C (FLNC) plays a critical role in maintaining the structural integrity of muscle cells, particularly within the cardiac sarcomere. Pathogenic variants in the FLNC gene are increasingly recognized as significant contributors to a diverse range of cardiomyopathies, including dilated (DCM), hypertrophic (HCM), arrhythmogenic (ACM), and restrictive cardiomyopathy (RCM). This review explores the genotype-phenotype correlations in FLNC-related cardiomyopathies, emphasizing how the type and location of genetic variants influence the clinical presentation. Truncating variants are primarily associated with DCM and [...] Abstract Filamin C (FLNC) plays a critical role in maintaining the structural integrity of muscle cells, particularly within the cardiac sarcomere. Pathogenic variants in the FLNC gene are increasingly recognized as significant contributors to a diverse range of cardiomyopathies, including dilated (DCM), hypertrophic (HCM), arrhythmogenic (ACM), and restrictive cardiomyopathy (RCM). This review explores the genotype-phenotype correlations in FLNC-related cardiomyopathies, emphasizing how the type and location of genetic variants influence the clinical presentation. Truncating variants are primarily associated with DCM and

1 January 2026 in Arquivos Brasileiros de Cardiologia
Verified
Journal Article
Open access
GRGiovanna Napolitano Pereira Ribeiro
Giovanna Napolitano Pereira Ribeiro
LLLayara Fernanda Vicente Pereira Lipari
Layara Fernanda Vicente Pereira Lipari
PSPaula Mendonça Senra
Paula Mendonça Senra
LPLucas Vieira Lacerda Pires
Lucas Vieira Lacerda Pires
MMMarjorie Hayashida Mizuta
Marjorie Hayashida Mizuta
JKJosé Eduardo Krieger
José Eduardo Krieger
Resumo A doença de Danon é uma doença rara ligada ao cromossomo X, causada por variantes patogênicas ou provavelmente patogênicas no gene da proteína 2 da membrana associada ao lisossomo (LAMP2). Manifesta-se principalmente como cardiomiopatia hipertrófica, miopatia, deficiência intelectual e retinopatia, sendo que os homens geralmente apresentam um fenótipo mais grave e de início precoce. A fisiopatologia da doença de Danon está ligada à autofagia defeituosa devido à deficiência de LAMP2, levando ao acúmulo de vacúolos cheios de glicogênio dentro dos cardiomiócitos e outros tecidos. Isso resulta em hipertrofia cardíaca progressiva, anormalidades de condução e eventual insuficiência cardíaca, frequentemente necessitando de transplante cardíaco. O envolvimento da musculatura esquelética é comum em homens, enquanto o comprometimento cognitivo é observado em ambos os sexos, embora mais prevalente em homens. O diagnóstico é desafiador devido à raridade da doença e à apresentação variável, o que destaca a necessidade de uma abordagem multidisciplinar, incluindo testes genéticos para um diagnóstico definitivo. Os testes genéticos devem ser realizados somente após aconselhamento genético adequado. O diagnóstico diferencial deve ser considerado quando há suspeita de doença de Danon, dependendo dos sinais e sintomas, incluindo doenças como a doença de Fabry, a síndrome PRKAG2, a doença de Pompe, entre outras. As estratégias de tratamento atuais focam no alívio dos sintomas, sendo o transplante cardíaco uma intervenção crucial para casos avançados. Terapias emergentes, como a terapia gênica direcionada ao gene LAMP2, podem auxiliar na alteração da progressão da doença. Esta revisão oferece uma visão abrangente da doença de Danon, abordando suas manifestações clínicas, mecanismos subjacentes, desafios diagnósticos e potenciais abordagens terapêuticas para melhorar os resultados. Nosso objetivo é aumentar o reconhecimento da doença de Danon para que a prevenção de possíveis complicações e o diagnóstico precoce se tornem viáveis, levando, em última análise, a desfechos mais favoráveis para os pacientes.